A Phase 3 interventional study of Amoxicillin and Benzyl penicillin in Pneumonia, sponsored by KEMRI-Wellcome Trust Collaborative Research Program. Completed at 6 sites in Kenya. Open to participants aged 2 Months to 59 Months. Per ClinicalTrials.gov, last updated 2015-02-13.
Sponsored by KEMRI-Wellcome Trust Collaborative Research Program · Phase 3, Interventional, and Treatment
This study seeks to determine whether clinical outcome following initial treatment of severe pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin. The study will also provide an estimate of the proportion of Kenyan children with severe pneumonia who fail treatment with a single antibiotic.
Case management for the treatment of childhood acute respiratory infections has been widely promoted in many developing countries for over 20 years. Despite this, pneumonia continues to claim over 1.5 million lives of children under five annually. The use of affordable, easily-administered, safe, effective treatments can potentially reduce the burden of childhood pneumonia. The WHO recommends the use of a single antibiotic for the treatment of severe pneumonia. Whereas in Asia, evidence from large randomized clinical trials has changed policy recommendations for treatment of severe pneumonia from parenteral penicillin to oral amoxicillin, there is little evidence to inform a similar move in African children where pneumonia is associated with poorer outcomes. In this study the investigators will investigate effectiveness of oral amoxicillin versus the current standard treatment, benzyl penicillin in severe childhood pneumonia using a randomized controlled non-inferiority design preceded by a pilot pre-intervention phase. The investigators will also collect observational data HIV-exposed / infected children with severe pneumonia. 594 children aged 2 - 59 months admitted with clinical signs of severe pneumonia to up to 7 hospitals in Kenya will be randomly assigned to receive either oral amoxicillin or injectable benzyl penicillin. They will then be followed up for the primary outcome of pre-defined treatment failure at 48 hours. The results of this trial will provide valuable data on the effectiveness of oral amoxicillin in the treatment of severe pneumonia in a population of Kenyan children and determine the practicability of conducting large pragmatic trials on pneumonia in Africa similar to those done in Asia.
1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.
This study's enrollment of 561 is above the median of 129 across 975 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →KEMRI-Wellcome Trust Collaborative Research Program is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Amoxicillin
Drug: Benzyl penicillin
Oral 45mg/kg 12 hourly
Intravenous 50,000IU/kg 6 hourly
Treatment Failure at 48 Hours (Two Full Days After Enrollment)
Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 \<85% or \<80% for altitude \< or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit
Time frame: 48 hours
Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)
Treatment failure as defined in the primary outcome measure.
Time frame: Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).
Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment
Time frame: Day 0 to Day 14
Death at or Before Five Days Following Enrollment
Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.
Time frame: Day 0 to Day 5
Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview
Definition of death as described in third secondary outcome measure.
Time frame: Day 14
| Milestone | Amoxicillin 45mg/kg 12 Hourly | Benzyl Penicillin 50,000IU/kg 6 Hourly |
|---|---|---|
| Started | 263 | 264 |
| Completed | 263 | 263 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 \<85% or \<80% for altitude \< or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit
| participants | Amoxicillin | Penicillin |
|---|---|---|
| Treatment Failure at 48 Hours (Two Full Days After Enrollment) | 20 | 21 |
Treatment failure as defined in the primary outcome measure.
| participants | Amoxicillin | Penicillin |
|---|---|---|
| Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First) | 30 | 29 |
Results for this outcome have not been posted.
Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.
Results for this outcome have not been posted.
Definition of death as described in third secondary outcome measure.
| participants | Amoxicillin | Penicillin |
|---|---|---|
| Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview | 33 | 42 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amoxicillin | — | 1/263 (0.4%) | 0/263 (0%) |
| Benzyl Penicillin | — | 3/263 (1.1%) | 0/263 (0%) |
| Event | Amoxicillin | Benzyl Penicillin |
|---|---|---|
| Congestive heart failureCardiac disorders | 1/263 | 0/263 |
| Hypovolemic shockGastrointestinal disorders | 0/263 | 1/263 |
| Renal failureRenal and urinary disorders | 0/263 | 1/263 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/263 | 1/263 |
| Age, Continuous(years) | Amoxicillin | Penicillin | Total |
|---|---|---|---|
| Median | 14 (7 to 25) | 13 (7 to 24) | 13 (7 to 24) |
| Sex: Female, Male(Participants) | Amoxicillin | Penicillin | Total |
|---|---|---|---|
| Female | 120 | 106 | 226 |
| Male | 143 | 158 | 301 |
| Region of Enrollment(participants) | Amoxicillin | Penicillin | Total |
|---|---|---|---|
| Kenya | 263 | 264 | 527 |
The record gives a start of Sep 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amoxicillin
KEMRI-Wellcome Trust Collaborative Research Program